Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $8.24

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned a consensus recommendation of “Hold” from the nine brokerages that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $8.24.

A number of brokerages have recently issued reports on ZNTL. UBS Group cut their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Finally, Wedbush restated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th.

Insider Activity at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns acquired 20,000 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were acquired at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the acquisition, the insider now owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth $37,000. Paloma Partners Management Co purchased a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at about $37,000. Corton Capital Inc. acquired a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $32,000. Captrust Financial Advisors acquired a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $33,000. Finally, Prudential Financial Inc. purchased a new position in Zentalis Pharmaceuticals during the fourth quarter valued at approximately $39,000.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $1.17 on Thursday. Zentalis Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $15.79. The company has a 50-day moving average of $1.95 and a 200 day moving average of $2.78. The firm has a market cap of $84.02 million, a PE ratio of -0.47 and a beta of 1.80.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. The business had revenue of $26.90 million for the quarter. Sell-side analysts anticipate that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.